JPRN-UMIN000007318
Completed
Phase 2
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancer - Topotecan plus oral etoposide in recurrent ovarian cancer
Kyorin University, School of Medicine0 sites20 target enrollmentFebruary 17, 2012
ConditionsResistant ovarian cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Resistant ovarian cancer
- Sponsor
- Kyorin University, School of Medicine
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with severe infectious disease and/or serious complication. 2\) Patients who have severe gastrointestinal injury and/or gastrointestinal bleeding. 3\) Patients who have necessary ascites and/or pleural effusion of measures. 4\) Patients with interstitial pneumonia. 5\) Patients with ileus. 6\) Patients with active brain metastases. 7\) Patients with active double cancer. 8\) Patients who carried out bone marrow transplantation. 9\) Patients who have the past of serious hypersensitivity. 10\) Patients who are pregnant or who are at risk of pregnancy, or those who desire to become pregnant during their participation. 11\) Patients who have uncontrolled diabetes mellitus. 12\) Patients who received topoisomerase I inhibitor and/or topoisomerase II inhibitor containing chemotherapy within 6 months. 13\) Inappropriate patients for this study judged by the physicians.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
Recruiting
Phase 2
Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancercolorectal cancerJPRN-UMIN000006793ippon Medical School Musashikosugi Hospital40
Completed
Phase 2
Phase II clinical trial of combination chemotherapy with bendamustine and rituximab for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patientsCD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaJPRN-UMIN000008024Kyoto University Hematology Study Group45
Active, not recruiting
Not Applicable
Klinisk prövning med kombinationsbehandling av kemoterapi och antikroppar för behandling av patienter med gallgångscancer som inte kan opereras.EUCTR2010-020385-13-SEVejle Hospital78
Active, not recruiting
Phase 1
Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations - GOC-B-PEUCTR2010-020385-13-DKVejle Hospital